All monoclonal antibodies articles
-
NewsImmunization to prevent RSV in infants reduced ICU admissions by 97 per cent
A new immunization, offered free to all infants through universal programs in two Canadian provinces, provided strong protection against respiratory syncytial virus, commonly referred to as RSV, sharply reducing hospitalizations and intensive care unit (ICU) admissions in infants.
-
NewsPre-existing antibodies linked to different immune responses after influenza vaccination
New study highlights how previous exposure to influenza viruses and vaccines can leave behind pre-existing antibodies, which may influence how the immune system responds to later vaccination.
-
NewsMount Sinai scientists develop first fully human monoclonal antibody cocktail that protects against Nipah and Hendra viruses
New preclinical study demonstrates that a novel monoclonal antibody cocktail provides complete protection against lethal Nipah and Hendra virus infection.
-
NewsHealth researchers call for support to develop pandemic prevention
The Vanderbilt Center for Antibody Therapeutics has received large-scale government grants and contracts to fund the discovery of human antiviral antibodies. The problem is the next step — finding corporate partners to develop the antibodies through human testing.
-
NewsExperts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus
In response to the current outbreak of Ebola disease caused by Bundibugyo virus, WHO convened several of its expert and advisory groups to assess potential vaccines and therapeutics for both prevention and treatment of Bundibugyo virus disease (BVD).
-
News Huayunuo approval positions China at forefront of viral hepatitis innovation, says GlobalData
Huahui Health has recently secured conditional approval from China for Huayunuo (Libevitug Injection), marking it as the first domestically developed monoclonal antibody (mAb) drug for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis.
-
NewsScientists develop first-of-its-kind antibody to block Epstein Barr virus
Using mice with human antibody genes, scientists have developed new genetically human monoclonal antibodies that prevent two key antigens on the surface of the Epstein Barr virus (EBV) from binding to and entering human immune cells.
-
NewsResearchers discover how a respiratory bacterium obtains essential lipids from the human body and targets fat-rich tissues
A multidisciplinary team has uncovered a key mechanism that allows the human bacterium Mycoplasma pneumoniae—responsible for atypical pneumonia and other respiratory infections—to obtain cholesterol and other essential lipids directly from the human body.
-
NewsGlobal Virus Network issues warning on the Marburg virus outbreak in Ethiopia
The Global Virus Network (GVN) has issued a statement on the newly confirmed outbreak of Marburg virus disease (MVD) in southern Ethiopia. This represents the country’s first documented outbreak of Marburg virus and raises urgent public health, research, and surveillance imperatives.
-
NewsGroundbreaking new projects launched to lower the cost of monoclonal antibody production
LifeArc and the Gates Foundation have awarded more than $5m to seven projects aimed at developing cheaper and more efficient ways to produce monoclonal antibody (mAb) treatments. The innovative approaches include using filamentous fungus to produce mAbs.
-
NewsNew monoclonal antibody shows promise for preventing malaria infections
A new early-stage clinical trial has found that a novel monoclonal antibody provided dose-dependent full protection against the malaria parasite with minimal side effects.
-
NewsVanderbilt and Parse Biosciences collaborate on new measles treatment
Vanderbilt University Medical Center and Parse Biosciences, an innovator in single-cell sequencing, are collaborating on a new treatment to help unvaccinated measles victims, as the U.S. measles outbreak has now reached its highest case count in 30 years.
-
NewsStudy uncovers how certain antibodies help fight tuberculosis
Researchers collected the largest library of monoclonal antibodies to Mycobacterium tuberculosis (Mtb) and identified specific antibody features that significantly limit its growth.
-
NewsClinical trial underway for potential Long COVID treatment
A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca’s long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential treatment for Long Covid.
-
NewsMonoclonal antibody nirsevimab provides strong protection against severe RSV in infants
Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, suggests a meta-analysis.
-
NewsTransatlantic collaboration to develop therapeutic for Crimean-Congo Hemorrhagic Fever
A new transatlantic collaboration will look to develop an affordable and accessible monoclonal antibody therapeutic for Crimean-Congo Hemorrhagic Fever Virus (CCHFV), which could treat and protect thousands of people globally.
-
NewsAntibody-based therapy is several steps closer to treat lethal mucormycosis
A new paper discusses the use of monoclonal antibodies to target a key fungal cell surface protein, CotH, which enables the Mucorales fungus to invade human cells and cause mucormycosis, which has high mortality rates in people with weakened immune systems.
-
NewsBAADesign enables the immune escaped etesevimab fully-armed against SARS-CoV-2 Omicron subvariants
BAADesign offers a powerful tool for reengineering monoclonal antibodies to combat emerging SARS-CoV-2 variants, providing a scalable solution for future pandemic preparedness, according to a new study.
-
NewsResearchers identify antibodies against Klebsiella pneumoniae
Researchers have identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of drug-resistant infections.
-
NewsAntiviral-resistant variants of SARS-CoV-2 can emerge in immunocompromised people
Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population.